Brainstorm Cell Therapeutics Inc. (BCLI)
NASDAQ: BCLI · Real-Time Price · USD
1.190
-0.070 (-5.56%)
At close: Apr 1, 2025, 4:00 PM
1.260
+0.070 (5.88%)
After-hours: Apr 1, 2025, 4:54 PM EDT
BCLI Employees
Brainstorm Cell Therapeutics had 29 employees as of December 31, 2023. The number of employees decreased by 14 or -32.56% compared to the previous year.
Employees
29
Change (1Y)
-14
Growth (1Y)
-32.56%
Revenue / Employee
n/a
Profits / Employee
-$400,793
Market Cap
6.79M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BCLI News
- 1 day ago - Brainstorm Cell Therapeutics Inc. (BCLI) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 1 day ago - BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 6 days ago - BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq - PRNewsWire
- 8 days ago - BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update - PRNewsWire
- 3 months ago - BrainStorm Issues 2024 Letter to Shareholders - PRNewsWire
- 4 months ago - BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update - PRNewsWire
- 4 months ago - BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology - PRNewsWire
- 4 months ago - BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024 - PRNewsWire